The Dow Jones Industrial Average fell as DuPont Co. and Travelers Cos. slumped after reporting results, while a takeover offer for Mylan NV pushed the Nasdaq Composite Index higher.
WASHINGTON, DC – A new study suggests that an investigational drug for multiple sclerosis (MS) may repair myelin, the fatty material that protects nerves and is damaged in MS, according to a study released today that will be presented at the American Academy of Neurology’s 67th Annual Meeting in Washington, DC, April 18 to 25, 2015.
Berkeley Researchers and Supercomputers to Help Create a Standard 3D Neuron Model Before scientists can unlock the secrets of the human brain, they must fully understand neurons—the cells of our brain, spinal cord and overall nervous system. Thousands of detailed neuron images, from different organisms, currently sit in individual data collections across the globe, comprising several petabytes of data altogether. Despite this plethora of data, made possible with advancements in brain cellular imaging, data standardization is still a major hurdle to gaining an accurate understanding about how neurons work.
Cambridge, Mass. April 1st, 2015 — A collaborative study between researchers from the Broad Institute of MIT and Harvard, Massachusetts Institute of Technology, and the National Center for Biotechnology Information of the National Institutes of Health (NIH-NCBI) has identified a highly efficient Cas9 nuclease that overcomes one of the primary challenges to in vivo genome editing. This finding, published today in Nature, is expected to help make the CRISPR toolbox accessible for in vivo experimental and therapeutic applications.
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients’ tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. The tailor-made vaccines, given to three patients with advanced melanoma, appeared to increase the number and diversity of cancer-fighting T cells responding to the tumors. The finding is a boost to cancer immunotherapy, a treatment strategy that unleashes the immune system to seek out and destroy cancer. The research is reported April 2 in Science Express, in a special issue devoted to cancer immunology and immunotherapy.